Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...
The Financial Express16h
Incyte’s skin disease drug meets main goal in late-stage studies
Hidradenitis suppurativa is an acne-like condition that causes painful bumps and lesions in and under the skin.
Agence France-Presse14h
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...
Interaksyon on MSN17h
‘Hang in there’: Celebs offer support to Kris Aquino as she shares health update
Various showbiz personalities expressed their support for former host-actress Kris Aquino who praised her youngest child, ...
Managed Healthcare Executive12h
FDA Grants Priority Review to Kerendia in Heart Failure
Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...
Le Lézard16h
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDxtm (glucagon) for Use as a Diagnostic Aid
Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...
Ophthalmology Advisor15h
FDA Drug Approval Decisions Expected in April 2025
Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.